Filing identity and reporting period
Important identity discrepancy: The request identifies LENZ Therapeutics, Inc., but the supplied filing is Graphite Bio, Inc. (Nasdaq: GRPH), a Delaware clinical-stage gene-editing company. This summary reflects the supplied Graphite Bio Form 10-Q, not a LENZ filing.
The filing reports unaudited results for the quarter and nine months ended September 30, 2021, compared with the corresponding 2020 periods. It was filed November 10, 2021.
Business context and financial results
Graphite Bio was developing gene-editing therapies and had no product sales or approved products. Its lead candidate, GPH101, targets sickle cell disease (SCD); other candidates were in preclinical or earlier development.
| Metric | Three months ended September 30, 2021 | Three months ended September 30, 2020 | Nine months ended September 30, 2021 | Nine months ended September 30, 2020 |
|---|---|---|---|---|
| Revenue | None reported | None reported | None reported | None reported |
| Research and development expense | $8.7 million | $2.3 million | $26.7 million | $2.7 million |
| General and administrative expense | $5.9 million | $1.5 million | $14.8 million | $2.4 million |
| Total operating expenses | $14.6 million | $3.8 million | $41.5 million | $5.2 million |
| Net loss | $14.6 million | $3.4 million | $51.8 million | $4.8 million |
| Net loss per share, basic and diluted | $0.28 | $1.00 | $2.51 | $2.53 |
Margins are not meaningful for this pre-revenue company. The nine-month 2021 net loss included a $10.3 million noncash loss from remeasuring a preferred-stock tranche liability.
Cash, liquidity and financing
- At September 30, 2021, cash and cash equivalents were $394.8 million; restricted cash was $0.1 million. Total assets were $416.2 million, total liabilities $16.0 million, and stockholders’ equity $400.1 million.
- Current assets were $401.2 million and current liabilities $11.3 million. Operating lease liabilities totaled $9.5 million; the filing reports no outstanding debt at period-end.
- For the first nine months of 2021, operating cash use was $37.3 million, investing cash use $4.8 million, and financing cash inflow $417.2 million. Financing included $251.3 million of net IPO proceeds and $165.5 million from preferred-stock issuance.
- The IPO issued 16.1 million shares at $17.00 per share. Preferred stock converted into common stock at the IPO; 58.1 million common shares were outstanding at September 30.
- Runway statements differ: the financial-statement notes say cash and restricted cash should fund the current operating plan for at least 12 months from issuance, while MD&A says existing cash should fund operating expenses and capital expenditures into 2024.
Changes, outlook and risks
- Year-over-year spending rose as the company expanded clinical and manufacturing work, personnel, facilities, and public-company operations. Nine-month R&D expense increased $24.0 million and G&A increased $12.4 million.
- Management said it intended to enroll the first patient in a GPH101 Phase 1/2 trial in the second half of 2021 and expected initial proof-of-concept data by the end of 2022. It also intended to file an IND for a second program by mid-2023.
- Management expected substantial losses and increasing expenses for the foreseeable future; profitability depends on successful development, regulatory approval, and commercialization. Additional capital may be needed, and the company warned that financing may not be available on acceptable terms.
- Key risks include early-stage clinical and gene-editing uncertainty, potential off-target effects and other safety issues, regulatory delays, patient enrollment, reliance on third-party manufacturers and suppliers, COVID-19 disruption, competition, and intellectual-property and licensing disputes.
- Manufacturing commitments include an exclusive LCGM suite through April 2023, with annual fees of $2.8 million. Stanford and IDT licenses also carry potential milestone, royalty, and other payment obligations; no milestones were reported as achieved or probable at quarter-end.
- The company reported no material legal proceedings, no material changes in internal control during the quarter, and no subsequent events through November 10, 2021.
Investor verification priorities
- Confirm the intended issuer: the supplied filing is Graphite Bio (GRPH), not LENZ Therapeutics.
- Reconcile the stated cash runway (“at least 12 months” versus “into 2024”) and review subsequent cash use and updated operating plans.
- Check whether GPH101 enrollment and the stated 2022 data target were achieved, and review clinical safety, efficacy, and trial progress.
- Assess the pace and drivers of operating cash burn, stock-based compensation, capital spending, and potential financing needs.
- Review third-party manufacturing capacity and the financial, diligence, and intellectual-property terms of the Stanford and IDT agreements.